| Synonyms |
2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, 1,9-bis(1-methylethyl) ester, 5-oxide; 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, bis(1-methylethyl) ester, 5-oxide; 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, bis(1-methylethyl) ester, 5-oxide, (R)-; Bis-POC-PMPA; GS 4331; 5-[[(1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]-bis(1-methylethyl)ester-5-oxide-2,4,6,8-tetraoxa-5-phosphanonanedioic Acid; (R)-5-[[2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]-bis(1-methylethyl)ester-5-oxide-2,4,6,8-tetraoxa-5-phosphanonanedioic Acid |
| IUPAC Name |
[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate |
| Molecular Weight |
519.44 |
| Molecular Formula |
C19H30N5O10P |
| Canonical SMILES |
CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C |
| InChI |
InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1 |
| InChIKey |
JFVZFKDSXNQEJW-CQSZACIVSA-N |
| Boiling Point |
642.7±65.0°C at 760 mmHg |
| Flash Point |
342.5±34.3 °C |
| Purity |
≥95% |
| Density |
1.45±0.1 g/cm3 |
| Solubility |
Soluble in DMSO |
| Appearance |
White to Off-white Solid |
| Storage |
Store in a cool and dry place and at 2-8°C for short term (days to weeks) or -20°C for long term (months to years) |
| Complexity |
698 |
| Exact Mass |
519.17302917 |
| Index Of Refraction |
1.578 |
| In Vitro |
Tenofovir shows cytotoxic effects on cell viability in HK-2 cells, with IC50 values of 9.21 and 2.77 μM at 48 and 72 h in MTT assay, respectively. Tenofovir diminishes ATP levels in HK-2 cells. Tenofovir (3.0 to 28.8 μM) increases oxidative stress and protein carbonylation in HK-2 cells. Furthermore, Tenofovir and M48U1 formulated in 0.25% HEC each inhibits the replication of both R5-tropic HIV-1BaL and X4-tropic HIV-1IIIb in activated PBMCs, and inhibits several laboratory strains and patient-derived HIV-1 isolates. The combined formulation of M48U1 and tenofovir in 0.25% HEC exhibits synergistic antiretroviral activity against infection with R5-tropic HIV-1BaL, and is not toxic to PBMCs. |
| In Vivo |
Tenofovir Disoproxil Fumarate (20, 50, 140, or 300 mg/kg) administered to BLT mice, shows dose dependent activity during vaginal HIV challenge in BLT humanized mice. Tenofovir Disoproxil Fumarate (50, 140, 300 mg/kg) significantly reduces HIV transmission in BLT mice. Tenofovir Disoproxil Fumarate (0.5, 1.5, or 5.0 mg/kg/day, p.o.) induces a dose-dependent decline in serum viremia in woodchucks chronically infected with WHV. Tenofovir Disoproxil Fumarate administration is safe and effective in the woodchuck model of chronic HBV infection. |
| PSA |
195.25000 |
| Target |
HIV; Reverse Transcriptase; HBV |
| Vapor Pressure |
0.0±1.9 mmHg at 25°C |
| XLogP3-AA |
1.6 |
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/201341-05-1.gif)
